ArticleJournal of lipids2011
Very-low-density lipoprotein: complex particles in cardiac energy metabolism.
Article in Journal of lipids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome.Lipids in health and disease · 2020Trial
- Single-nucleus transcriptome inventory of giant panda reveals cellular basis for fitness optimization under low metabolism.BMC biology · 2023Article
- Modulation of MAPK/NF-κB Pathway and NLRP3 Inflammasome by Secondary Metabolites from Red Algae: A Mechanistic Study.ACS omega · 2023Article
- Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights.Frontiers in cardiovascular medicine · 2022Review
- The Pathogenic Role of Very Low Density Lipoprotein on Atrial Remodeling in the Metabolic Syndrome.International journal of molecular sciences · 2020Review
- Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action.Journal of atherosclerosis and thrombosis · 2018Review
- Retinal energy demands control vascular supply of the retina in development and disease: The role of neuronal lipid and glucose metabolism.Progress in retinal and eye research · 2018Review
- Polyhedral 3D structure of human plasma very low density lipoproteins by individual particle cryo-electron tomography1.Journal of lipid research · 2016Article
- Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1.Nature medicine · 2016Article
- Fatty Acid Oxidation and Cardiovascular Risk during Menopause: A Mitochondrial Connection?Journal of lipids · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heart is a major consumer of energy and is able to utilise a wide range of substrates including lipids. Nonesterified fatty acids (NEFA) were thought to be a favoured carbon source, but their quantitative contribution is limited because of their relative histotoxicity. Circulating triacylglycerols (TAGs) in the form of chylomicrons (CMs) and very-low-density lipoprotein (VLDL) are an alternative source of fatty acids and are now believed to be important in cardiac metabolism. However, few studies on cardiac utilisation of VLDL have been performed and the role of VLDL in cardiac energy metabolism remains unclear. Hearts utilise VLDL to generate ATP, but the oxidation rate of VLDL-TAG is relatively low under physiological conditions; however, in certain pathological states switching of energy substrates occurs and VLDL may become a major energy source for hearts. We review research regarding myocardial utilisation of VLDL and suggest possible roles of VLDL in cardiac energy metabolism: metabolic regulator and extracardiac energy storage for hearts.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.